Research and Markets: Global Cardiovascular Disorders Drug Pipeline Capsule - 2012

Research and Markets: Global Cardiovascular Disorders Drug Pipeline Capsule - 2012

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Fore Pharma's latest report Global Cardiovascular Disorders Drug Pipeline Capsule - 2012' provides up-to-date information on key research and development activities in the global cardiovascular disorders drug market. It covers active pipeline molecules under development in various stages of clinical trials, preclinical research, and drug discovery for Acute Coronary Syndrome, Hypertension, Myocardial Infarction, Pulmonary Hypertension, Stroke, and Thrombosis.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating business opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company, mechanism of action, stage (phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and drug discovery), and geography (North America, Europe, and Asia).

- Cardiovascular Disorders Drug Pipeline Insights

- Acute Coronary Syndrome Drug Pipeline Insights

- Hypertension Drug Pipeline Insights

- Myocardial Infarction Drug Pipeline Insights

- Pulmonary Hypertension Drug Pipeline Insights

- Stroke Drug Pipeline Insights

- Thrombosis Drug Pipeline Insights

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.